Search
Search Results
-
Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy
Granulocyte transfusions are sometimes used as adjunctive therapy for the treatment of infection in patients with chronic granulomatous disease...
-
Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery
Platelets are small anucleated blood cells primarily known for their vital hemostatic role. Allogeneic platelet concentrates (PCs) collected from...
-
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection....
-
-
-
Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients received allogeneic hematopoietic stem cell transplantation
BackgroundMethotrexate (MTX) is used to treat graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation...
-
Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for high-risk hematologic disorders. There are multiple...
-
-
There is no dose–response relationship between allogeneic blood transfusion and healthcare-associated infection: a retrospective cohort study
BackgroundThe association between allogeneic blood transfusion and healthcare-associated infection (HAI) is considered dose-dependent. However, this...
-
Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia
BackgroundTransplantation-related mortality (TRM) is a major obstacle in allogeneic hematopoietic cell transplantation (allo-HCT). Approximately...
-
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial
The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis is not established after reduced intensity...
-
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia
Beta-thalassemia ( β -thalassemia) is an autosomal recessive disorder caused by point mutations, insertions, and deletions in the HBB gene cluster,...
-
-
Perfluorocarbon-based artificial oxygen carriers for red blood cell substitutes: considerations and direction of technology
BackgroundRecently, the development of an artificial oxygen carrier that can replace blood transfusions is gaining attention, particularly in...
-
Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome
BackgroundThe mixed-lineage leukemia ( MLL ) gene is located on chromosome 11q23. The MLL gene can be rearranged to generate partial tandem...
-
Pre-operative anemia and peri-operative transfusion are associated with poor oncologic outcomes in cancers of the esophagus: potential impact of patient blood management on cancer outcomes
BackgroundBoth Red Blood Cell (RBC) transfusion and anemia are thought to negatively impact cancer survival. These effects have been reported with...
-
The impact of ageing on the distribution of preformed anti-HLA and anti-MICA antibody specificities in recipients from eastern China prior to initial HSCT
BackgroundWith the development of Hematopoietic Stem Cell Transplantation (HSCT) technology, increasing numbers of elderly patients were undergoing...
-
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 (
... 
-
